Following the recent release of updated NICE guidance documents, John Hampson, Lead for Medicines Managment at Champs Support Team, has reviewed all updates and has produced a summary for each update.
John highlightes the below as most relevant to Public Helath and CCG's
- CCGs will be interested to note the following new TAGs, which are not expected to have significant cost impacts. These include TA448: eltelcalcetide for hyperparathyroidism , TA455:adalimumab etc for plaque psoriasis in children, TA456: ustekinumab for crohn’s, TA459: collagenase clostridium for Dupuytren’s, TA460: adalimumab for uveitis and TA461: roflumilast for COPD.
- Also of interest to CCGs is NG71:Parkinson’s disease – this might require a GP education programme.
- For Local Authorities NG 70: Air pollution is a key document which will be of relevance to planning, highways and transport, public health and environmental health.
- Finally, also of interest to LAs is QS:151 oral health in care homes.